{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "bad32605",
   "metadata": {},
   "source": [
    "# RAG Pipeline Exercise\n",
    "\n",
    "In this exercise you will build and **compare two simple Retrieval-Augmented Generation (RAG) pipelines**.\n",
    "\n",
    "You will work with a small collection of PDF documents (e.g. medical guidelines) and:\n",
    "\n",
    "1. Load and chunk the PDF documents.\n",
    "2. Create a vector index using **embedding model A** (local `BAAI/bge-m3`).\n",
    "3. Create a second index using **embedding model B** (e.g. OpenAI or Gemini embeddings).\n",
    "4. Implement a simple **retriever** and an **answering function** that calls an LLM with retrieved context.\n",
    "5. Automatically **generate questions** from the documents and use them to **compare two RAG configurations**.\n",
    "\n",
    "Cells marked with `# TODO` are **for students to implement**.\n",
    "Everything else is provided scaffolding."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4ddf82e6",
   "metadata": {},
   "source": [
    "## 0. Setup & Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "be93ec53",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WARNING:tensorflow:From c:\\Users\\Phil\\AppData\\Local\\Programs\\Python\\Python313\\Lib\\site-packages\\tf_keras\\src\\losses.py:2976: The name tf.losses.sparse_softmax_cross_entropy is deprecated. Please use tf.compat.v1.losses.sparse_softmax_cross_entropy instead.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# TODO (easy): skim the imports and make sure you understand what each library is used for.\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import glob\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "import faiss\n",
    "from sentence_transformers import SentenceTransformer\n",
    "import pickle\n",
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "# LLM / API clients (we will mainly use OpenAI here; Gemini can be added as a bonus)\n",
    "from openai import OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "68f16980",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load API keys from .env (you need to create this file once and add your keys)\n",
    "load_dotenv()\n",
    "\n",
    "deepinfra_key = os.getenv(\"DEEPINFRA_API_KEY\")\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "google_api_key = os.getenv(\"GOOGLE_API_KEY\")\n",
    "anthropic_api_key = os.getenv(\"ANTHROPIC_API_KEY\")\n",
    "\n",
    "# For this exercise we mainly use OpenAI for both embeddings (RAG B) and chat completions.\n",
    "assert openai_api_key is not None, \"Please set OPENAI_API_KEY in your .env file.\"\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "23ebcf52",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Make pandas show the full table and full cell content\n",
    "pd.set_option(\"display.max_rows\", None)       # show all rows\n",
    "pd.set_option(\"display.max_columns\", None)    # show all columns\n",
    "pd.set_option(\"display.max_colwidth\", None)   # don't truncate cell text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fba2719d",
   "metadata": {},
   "source": [
    "## 1. Load PDF documents\n",
    "\n",
    "We assume there is a `data/` folder containing one or more PDF files.\n",
    "\n",
    "**Task:** implement `load_pdfs(glob_path)` so that it:\n",
    "- Iterates over all PDF files matching `glob_path`\n",
    "- Reads them with `PdfReader`\n",
    "- Concatenates the text of all pages into **one long string**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "d8abcb21",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_pdfs(glob_path: str = \"data/*.pdf\") -> str:\n",
    "    \"\"\"Load all PDFs matching the pattern and return their combined text.\n",
    "\n",
    "    TODO:\n",
    "    - Use `glob.glob(glob_path)` to iterate over file paths\n",
    "    - For each file, open it in binary mode and create a `PdfReader`\n",
    "    - Loop over `reader.pages` and extract text with the extract_text() function\n",
    "    - Concatenate everything into a single string `text`\n",
    "    - Be robust: skip pages where `extract_text()` returns None\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    text = \"\"\n",
    "    for pdf_path in glob.glob(glob_path):\n",
    "        with open(pdf_path, \"rb\") as f:\n",
    "            reader = PdfReader(f)\n",
    "            for page in reader.pages:\n",
    "                page_text = page.extract_text()\n",
    "                if page_text:\n",
    "                    text += \" \" + page_text\n",
    "    return text\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "416c3ad0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of characters: 230708\n",
      "Preview:  Asthma: diagnosis, \n",
      "moni toring and chr onic \n",
      "asthma manag emen t (BTS, \n",
      "NICE, SI GN) \n",
      "NICE guideline \n",
      "Published: 27 No vember 202 4 \n",
      "www .nice.or g.uk/guidance/ng2 45 \n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s). Your r esponsi bility \n",
      "The r ecommendations in t his guideline r epresent t he view of NICE, arriv ed at aft er car eful \n",
      "consideration of t he evidence a vailable. When e xercising t heir judg\n"
     ]
    }
   ],
   "source": [
    "# Run once and inspect\n",
    "raw_text = load_pdfs(\"data/*.pdf\")\n",
    "print(\"Number of characters:\", len(raw_text))\n",
    "print(\"Preview:\", raw_text[:500])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5c0c5a14",
   "metadata": {},
   "source": [
    "## 2. Chunk the text\n",
    "\n",
    "We will split the long text into overlapping chunks.\n",
    "\n",
    "Later you can **experiment** with different `chunk_size` and `chunk_overlap` to see how it affects retrieval.\n",
    "\n",
    "**Task:** start with the given parameters, run once, then try at least one alternative configuration and note the effects."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "a4e3f802",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG A: 130 chunks produced, first chunk length = 1995\n",
      "RAG B: 260 chunks produced, first chunk length = 979\n"
     ]
    }
   ],
   "source": [
    "# Base configuration (RAG A)\n",
    "chunk_size_a = 2000\n",
    "chunk_overlap_a = 200\n",
    "\n",
    "splitter_a = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_a,\n",
    "    chunk_overlap=chunk_overlap_a\n",
    ")\n",
    "\n",
    "chunks_a = splitter_a.split_text(raw_text)\n",
    "print(f\"RAG A: {len(chunks_a)} chunks produced, first chunk length = {len(chunks_a[0])}\")\n",
    "\n",
    "# TODO (mini-experiment): change chunk_size / chunk_overlap for RAG B and compare\n",
    "chunk_size_b = 1000   # e.g. smaller chunks\n",
    "chunk_overlap_b = 100\n",
    "\n",
    "splitter_b = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_b,\n",
    "    chunk_overlap=chunk_overlap_b\n",
    ")\n",
    "\n",
    "chunks_b = splitter_b.split_text(raw_text)\n",
    "print(f\"RAG B: {len(chunks_b)} chunks produced, first chunk length = {len(chunks_b[0])}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ec3511f4",
   "metadata": {},
   "source": [
    "## 3. Create embeddings and a FAISS index\n",
    "\n",
    "We start with **Embedding model A: `BAAI/bge-small-en`** using `sentence-transformers`.\n",
    "\n",
    "Then, as an optional extension, you can build **Embedding model B** using OpenAI or Gemini and compare.\n",
    "\n",
    "To keep the exercise manageable, the base version only **requires** BGE."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b519161f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Embedding dimensionality (A): 384\n",
      "FAISS index (A) size: 130\n"
     ]
    }
   ],
   "source": [
    "# Embedding model A (local)\n",
    "model_name_a = \"BAAI/bge-small-en\"\n",
    "embedder_a = SentenceTransformer(model_name_a)\n",
    "\n",
    "# Compute embeddings for all chunks of configuration A\n",
    "embeddings_a = embedder_a.encode(chunks_a, convert_to_numpy=True)\n",
    "\n",
    "dimensions_a = embeddings_a.shape[1]\n",
    "print(\"Embedding dimensionality (A):\", dimensions_a)\n",
    "\n",
    "index_a = faiss.IndexFlatL2(dimensions_a)\n",
    "index_a.add(embeddings_a)\n",
    "print(\"FAISS index (A) size:\", index_a.ntotal)\n",
    "\n",
    "# Persist index/chunks if you like (optional)\n",
    "os.makedirs(\"faiss\", exist_ok=True)\n",
    "faiss.write_index(index_a, \"faiss/faiss_index_a.index\")\n",
    "with open(\"faiss/chunks_a.pkl\", \"wb\") as f:\n",
    "    pickle.dump(chunks_a, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "77271916",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "FAISS index (B) size: 260\n"
     ]
    }
   ],
   "source": [
    "# Embedding model B using OpenAI embeddings.\n",
    "\n",
    "# TODO:\n",
    "# - Use `openai_client.embeddings.create(...)` to compute embeddings for `chunks_b`\n",
    "# - Create a second FAISS index `index_b`\n",
    "# - Make sure to check the dimensionality from the first embedding vector\n",
    "\n",
    "# Example sketch (not complete, adapt & run if you have API access):\n",
    "# Initialize OpenAI client\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n",
    "response = openai_client.embeddings.create(\n",
    "     model=\"text-embedding-3-small\",\n",
    "    input=chunks_b\n",
    ")\n",
    "embeddings_b = np.array([item.embedding for item in response.data])\n",
    "dim_b = embeddings_b.shape[1]\n",
    "index_b = faiss.IndexFlatL2(dim_b)\n",
    "index_b.add(embeddings_b)\n",
    "print(\"FAISS index (B) size:\", index_b.ntotal)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0339224e",
   "metadata": {},
   "source": [
    "## 4. Implement a simple retriever\n",
    "\n",
    "We now implement a generic retrieval function that:\n",
    "1. Embeds the query.\n",
    "2. Searches the FAISS index.\n",
    "3. Returns the corresponding text chunks.\n",
    "\n",
    "We implement it for configuration A. If you built configuration B, you can reuse the same function."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "aa6fbf82",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of retrieved chunks: 3\n",
      "Preview of first chunk: and signs of ot her causes of r espirat ory sympt oms but be awar e that e ven if \n",
      "examination r esult s are normal, t he person ma y still ha ve ast hma. [NICE 2017] \n",
      "Initial tr eatmen t and obje ctive tests f or acu te sym ptoms a t \n",
      "presen tation \n",
      "1.1.5 Treat people immediat ely if t hey are acut ely unw ell or highly sympt omatic at \n",
      "presentation, and per form objectiv e tests that ma y help s\n"
     ]
    }
   ],
   "source": [
    "def retrieve_texts(query: str, k: int, index, chunks, embedder) -> list:\n",
    "    \"\"\"Return the top-k most similar chunks for a query.\n",
    "\n",
    "    TODO (students):\n",
    "    - Encode the query with `embedder.encode(...)`\n",
    "    - Call `index.search(query_embedding, k)`\n",
    "    - Use the returned indices to select the chunks\n",
    "    - Return a list of strings (chunks)\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    query_emb = embedder.encode([query], convert_to_numpy=True)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved\n",
    "\n",
    "# Quick sanity check\n",
    "test_query = \"What is the most important factor in diagnosing asthma?\"\n",
    "retrieved_text = retrieve_texts(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a)\n",
    "print(\"Number of retrieved chunks:\", len(retrieved_text))\n",
    "print(\"Preview of first chunk:\", retrieved_text[0][:400])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "84287470",
   "metadata": {},
   "outputs": [],
   "source": [
    "def openai_embed_query(query: str) -> np.ndarray:\n",
    "    \"\"\"\n",
    "    Compute an OpenAI embedding for a single query string and\n",
    "    return it as a NumPy array of shape (1, dim).\n",
    "    \"\"\"\n",
    "    resp = openai_client.embeddings.create(\n",
    "        model=\"text-embedding-3-small\",\n",
    "        input=[query]  # list with one string\n",
    "    )\n",
    "    vec = np.array(resp.data[0].embedding, dtype=\"float32\")\n",
    "    return vec.reshape(1, -1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "68ab8b40",
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_texts_b(query: str, k: int, index, chunks) -> list:\n",
    "    \"\"\"\n",
    "    Retrieve top-k chunks using OpenAI embeddings for the query.\n",
    "    \"\"\"\n",
    "    query_emb = openai_embed_query(query)  # shape (1, dim)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f646fdc6",
   "metadata": {},
   "source": [
    "## 5. Implement `answer_query` using an LLM\n",
    "\n",
    "Now we build the actual RAG call:\n",
    "\n",
    "1. Use `retrieve_texts` to get top-`k` chunks.\n",
    "2. Concatenate them into a context string.\n",
    "3. Build a prompt that:\n",
    "   - shows the context\n",
    "   - asks the model to answer the user question based **only** on this context.\n",
    "4. Call the OpenAI chat completion API.\n",
    "\n",
    "This is the **core RAG function**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "0d94610c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG answer: The context does not specify a single most important factor in diagnosing asthma. It mentions various objective tests that may help support a diagnosis, such as eosinophil count, fractional exhaled nitric oxide (FeNO), spirometry, and peak expiratory flow (PEF). Each of these can provide valuable information in the diagnosis process.\n"
     ]
    }
   ],
   "source": [
    "def answer_query_a(query: str, k: int, index, chunks, embedder, client: OpenAI) -> str:\n",
    "    \"\"\"RAG-style answer: retrieve context and ask an LLM.\n",
    "\n",
    "    TODO (students):\n",
    "    - Use `retrieve_texts` to get `k` relevant chunks.\n",
    "    - Join them into a single context string.\n",
    "    - Build a chat prompt that instructs the model to answer *only* using the context.\n",
    "    - Call `client.chat.completions.create(...)` with model `\"gpt-4o-mini\"` (or similar).\n",
    "    - Return the model's answer text.\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts(query, k, index, chunks, embedder)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"}\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()\n",
    "\n",
    "# Quick manual test\n",
    "answer = answer_query_a(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a, client=openai_client)\n",
    "print(\"RAG answer:\", answer)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4b13aade",
   "metadata": {},
   "source": [
    "### Answer Function with the other embedding type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "5994c414",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_query_b(query: str, k: int, index, chunks, client: OpenAI) -> str:\n",
    "    \"\"\"\n",
    "    RAG-style answer for configuration B (OpenAI embeddings + chunking B).\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts_b(query, k, index, chunks)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"},\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages,\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a86a92e",
   "metadata": {},
   "source": [
    "## 6. Generate questions from random chunks (automatic evaluation set)\n",
    "\n",
    "To compare two RAG configurations, we need **questions**.\n",
    "\n",
    "We will:\n",
    "- randomly sample a few chunks from the corpus,\n",
    "- ask an LLM to generate a **good question** whose answer is contained in the chunk.\n",
    "\n",
    "Then we can use these question–chunk pairs as a small evaluation set.\n",
    "\n",
    "We provide most of the implementation. Your job is mainly to:\n",
    "- inspect the code,\n",
    "- understand the prompt,\n",
    "- maybe tweak the number of chunks or retries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "eb899fb6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: What diagnostic criteria and tests are recommended for confirming asthma when spirometry is unavailable, and what steps should be taken if the diagnosis remains uncertain?\n",
      "  From chunk preview: [BTS/NICE/SIGN 202 4] \n",
      "1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks...\n",
      "\n",
      "Q2: What are the recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids and the evaluation of treatment efficacy after an initial trial period?\n",
      "  From chunk preview: childr en under 5 . \n",
      "1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \n",
      "corticost eroid ...\n",
      "\n",
      "Q3: What are the potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients?\n",
      "  From chunk preview: The studies f eatur ed diff ering wa ys of att empting t o impr ove ast hma car e for people \n",
      "judged t o be at high risk...\n",
      "\n",
      "Q4: What are the different blood pressure treatment thresholds and intervention recommendations for adults under 40 and those over 80, and what factors influenced the committee's recommendations for research in these areas?\n",
      "  From chunk preview: see t he rationale on monit oring tr eatment and blood pr essur e tar gets for people \n",
      "without car diovascular disease ....\n",
      "\n",
      "Q5: What considerations should healthcare providers keep in mind when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension, particularly regarding potassium levels and renal function?\n",
      "  From chunk preview: clarification on br eastf eeding . \n",
      "1.4.49 Consider fur ther diur etic t herap y wit h low-dose spir onolact one f or ad...\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def generate_questions_for_random_chunks(chunks, num_chunks: int = 5, max_retries: int = 2):\n",
    "    selected_chunks = random.sample(chunks, num_chunks)\n",
    "    qa_pairs = []\n",
    "\n",
    "    for chunk in selected_chunks:\n",
    "        prompt = prompt = (\n",
    "            \"Based on the following text, generate an insightful question that covers its key content:\\n\\n\"\n",
    "            \"Text:\\n\" + chunk + \"\\n\\n\"\n",
    "            \"Question:\"\n",
    "        )\n",
    "\n",
    "        question = None\n",
    "        for attempt in range(max_retries):\n",
    "            try:\n",
    "                completion = openai_client.chat.completions.create(\n",
    "                    model=\"gpt-4o-mini\",\n",
    "                    messages=[{\"role\": \"user\", \"content\": prompt}]\n",
    "                )\n",
    "                question = completion.choices[0].message.content.strip()\n",
    "                if question:\n",
    "                    break\n",
    "            except Exception as e:\n",
    "                print(\"Error while generating question, retrying...\", e)\n",
    "\n",
    "        if question is None:\n",
    "            question = \"Error: could not generate question.\"\n",
    "\n",
    "        qa_pairs.append((chunk, question))\n",
    "\n",
    "    return qa_pairs\n",
    "\n",
    "questions = generate_questions_for_random_chunks(chunks_a, num_chunks=5, max_retries=2)\n",
    "for i, (chunk, q) in enumerate(questions, 1):\n",
    "    print(f\"Q{i}: {q}\\n  From chunk preview: {chunk[:120]}...\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3fd0eaf5",
   "metadata": {},
   "source": [
    "## 7. Compare two RAG configurations\n",
    "\n",
    "Now we can:\n",
    "- Use the generated questions,\n",
    "- Answer them with RAG configuration A (BGE + chunking A),\n",
    "- (Optional) Answer them with RAG configuration B (e.g. different chunking and/or different embeddings),\n",
    "- Compare the answers qualitatively.\n",
    "\n",
    "To keep the exercise manageable, we start with config A only.\n",
    "If you implemented config B, reuse `answer_query` with `index_b`, `chunks_b`, and your second embedder."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "a292474a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What diagnostic criteria and tests are recommended for confirming asthma when spirometry is unavailable, and what steps should be taken if the diagnosis remains uncertain?\n",
      "Answer A: If spirometry is unavailable or delayed, it is recommended to measure peak expiratory flow (PEF) twice daily for 2 weeks. Asthma can be diagnosed if PEF variability (expressed as amplitude percentage mean) is 20% or more. \n",
      "\n",
      "If asthma is not confirmed by fractional exhaled nitric oxide (FeNO), bronchodilator reversibility (BDR), or PEF variability but is still suspected on clinical grounds, one should either perform skin prick testing to house dust mite or measure total IgE level and blood eosinophil count. \n",
      "\n",
      "- Exclude asthma if there is no evidence of sensitization to house dust mite on skin prick testing or if the total serum IgE is not raised. \n",
      "- Diagnose asthma if there is evidence of sensitization or a raised total IgE level, and the eosinophil count is more than 0.5 x 10^9 per liter. \n",
      "\n",
      "If there is still doubt about the diagnosis, a referral to a pediatric specialist for a second opinion, including consideration of a bronchial challenge test, should be made.\n",
      "Source chunk preview: [BTS/NICE/SIGN 202 4] \n",
      "1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \n",
      "Diagnose ast hma if PEF v a ...\n",
      "------------------------------------------------------------\n",
      "Question: What are the recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids and the evaluation of treatment efficacy after an initial trial period?\n",
      "Answer A: For managing suspected asthma in children under 5, the recommended steps regarding the use of inhaled corticosteroids (ICS) and the evaluation of treatment efficacy after an initial trial period are as follows:\n",
      "\n",
      "1. **Trial of ICS**: Consider an 8 to 12 week trial of twice-daily low-dose inhaled corticosteroid (ICS) as maintenance therapy, with a short-acting beta 2 agonist (SABA) for reliever therapy, if the child has symptoms indicating the need for maintenance therapy or has experienced severe acute episodes requiring hospitalization or multiple courses of oral corticosteroids.\n",
      "\n",
      "2. **Evaluation After Trial Period**: After the trial period, if symptoms do not resolve, take the following sequential steps:\n",
      "   - Check inhaler technique and adherence.\n",
      "   - Check for environmental sources of symptoms (e.g., mold, smoke, air pollution).\n",
      "   - Review whether an alternative diagnosis is likely.\n",
      "   - If none of these factors explain the failure to respond to treatment, refer the child to a specialist in asthma care.\n",
      "\n",
      "3. **Stopping Treatment**: If symptoms are resolved after the trial of ICS, consider stopping the ICS and SABA treatment after 8 to 12 weeks, and then review the symptoms after a further 3 months.\n",
      "\n",
      "4. **Management of Symptom Recurrence**: If symptoms resolve during the trial period but then recur by the 3-month review or if an acute episode requiring systemic corticosteroids or hospitalization occurs, restart regular ICS (starting at a low pediatric dose and titrating up to a moderate dose if needed) with SABA as needed, and consider a further trial without treatment after a subsequent review.\n",
      "\n",
      "5. **Further Treatment Options**: If asthma is uncontrolled on a moderate dose of ICS, consider adding a leukotriene receptor antagonist (LTRA) for a trial period of 8 to 12 weeks. If the LTRA is ineffective or not tolerated, refer the child to a specialist for further investigation and management. \n",
      "\n",
      "These steps aim to carefully monitor and adjust treatment, ensuring that the child receives appropriate care based on their response to initial therapies.\n",
      "Source chunk preview: childr en under 5 . \n",
      "1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \n",
      "corticost eroid (ICS) as maint enance t herap  ...\n",
      "------------------------------------------------------------\n",
      "Question: What are the potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients?\n",
      "Answer A: Implementing a risk-stratification system in primary care for improving asthma management among high-risk patients may have several implications:\n",
      "\n",
      "1. **Tailored Care**: It allows healthcare providers to actively identify individuals at risk of poor asthma outcomes and tailor care according to their specific needs.\n",
      "\n",
      "2. **Improved Identification**: By using alerts on GP computer systems, healthcare professionals can better identify patients who need interventions, such as a course of oral corticosteroids.\n",
      "\n",
      "3. **Reduction in Hospitalisation**: Studies show that risk stratification can lead to a reduction in emergency department attendances and hospitalisations for asthma exacerbations.\n",
      "\n",
      "4. **Cost-Effectiveness**: There is evidence suggesting that implementing risk stratification is likely to be cost-effective, as it can reduce the demand for emergency care and hospital admissions.\n",
      "\n",
      "5. **Enhanced Resource Allocation**: Primary care services can prioritize resources and focus on patients who are more likely to benefit from additional support and interventions.\n",
      "\n",
      "Overall, risk stratification is likely to improve asthma management and outcomes for high-risk patients while also being a more efficient use of healthcare resources.\n",
      "Source chunk preview: The studies f eatur ed diff ering wa ys of att empting t o impr ove ast hma car e for people \n",
      "judged t o be at high risk of adv erse out comes. Ther e ...\n",
      "------------------------------------------------------------\n",
      "Question: What are the different blood pressure treatment thresholds and intervention recommendations for adults under 40 and those over 80, and what factors influenced the committee's recommendations for research in these areas?\n",
      "Answer A: For adults under 40, the committee noted a lack of evidence to inform a specific threshold for starting treatment, indicating that this is an important area for future research. They carried forward a recommendation for research from the 2011 guideline regarding thresholds for interventions in this age group.\n",
      "\n",
      "For adults over 80, the recommended threshold for starting treatment should be consistent with the target for treatment in this population, which is 150/90 mmHg or lower. The committee acknowledged additional risks associated with starting treatment in older adults, particularly those who are frail or have multiple comorbidities. They emphasized the importance of using clinical judgment in decision-making for these individuals.\n",
      "\n",
      "The committee's recommendations for research in these areas were influenced by the insufficient evidence available for determining appropriate thresholds for starting treatment in both age groups, highlighting the need for more focused studies.\n",
      "Source chunk preview: see t he rationale on monit oring tr eatment and blood pr essur e tar gets for people \n",
      "without car diovascular disease . \n",
      "Full details of t he evidenc ...\n",
      "------------------------------------------------------------\n",
      "Question: What considerations should healthcare providers keep in mind when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension, particularly regarding potassium levels and renal function?\n",
      "Answer A: Healthcare providers should consider the following when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension:\n",
      "\n",
      "1. **Potassium Levels**: \n",
      "   - For patients starting step 4 treatment with resistant hypertension who have a blood potassium level of 4.5 mmol/l or less, further diuretic therapy with low-dose spironolactone may be considered.\n",
      "   - If a patient has a blood potassium level of more than 4.5 mmol/l, considering an alpha-blocker or beta-blocker instead might be appropriate.\n",
      "\n",
      "2. **Renal Function**:\n",
      "   - Special caution should be exercised in individuals with a reduced estimated glomerular filtration rate, as they have an increased risk of developing hyperkalaemia (elevated potassium levels).\n",
      "\n",
      "3. **Monitoring**: \n",
      "   - Blood sodium and potassium levels, along with renal function, should be monitored within 1 month of starting treatment and repeated as needed thereafter.\n",
      "\n",
      "These considerations are essential to minimize the risks associated with hyperkalaemia and ensure patient safety while managing resistant hypertension.\n",
      "Source chunk preview: clarification on br eastf eeding . \n",
      "1.4.49 Consider fur ther diur etic t herap y wit h low-dose spir onolact one f or adult s wit h \n",
      "resistant h yper  ...\n",
      "------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "def answer_generated_questions_a(question_tuples, k, index, chunks, embedder, client):\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_a(question, k, index, chunks, embedder, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer\n",
    "        })\n",
    "    return results\n",
    "\n",
    "results_a = answer_generated_questions_a(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_a,\n",
    "    chunks=chunks_a,\n",
    "    embedder=embedder_a,\n",
    "    client=openai_client,\n",
    ")\n",
    "\n",
    "for item in results_a:\n",
    "    print(\"Question:\", item[\"question\"])\n",
    "    print(\"Answer A:\", item[\"answer\"])\n",
    "    print(\"Source chunk preview:\", item[\"chunk\"][:150], \"...\")\n",
    "    print(\"-\" * 60)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ec212b7",
   "metadata": {},
   "source": [
    "### Extension: add RAG B and create a comparison table\n",
    "\n",
    "If you implemented a second configuration (e.g. different chunking + OpenAI embeddings):\n",
    "\n",
    "1. Build `index_b` using OpenAI embeddings and `chunks_b`.\n",
    "2. Implement `openai_embed_query`, `retrieve_texts_b`, and `answer_query_b`.\n",
    "3. Run `results_b = answer_generated_questions_b(questions, k=5, index=index_b, chunks=chunks_b, client=openai_client)`.\n",
    "4. For each question, compare:\n",
    "   - Which answer is more complete / specific?\n",
    "   - Which one is better grounded in the source chunk?\n",
    "5. Summarise your findings in a short **markdown cell** or a small table.\n",
    "\n",
    "---\n",
    "\n",
    "This concludes the core RAG exercise.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "faa74961",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_generated_questions_b(question_tuples, k, index, chunks, client):\n",
    "    \"\"\"\n",
    "    Use RAG B to answer a list of (chunk, question) pairs.\n",
    "    \"\"\"\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_b(question, k, index, chunks, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer,\n",
    "        })\n",
    "    return results\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "e9ee1310",
   "metadata": {},
   "outputs": [],
   "source": [
    "results_b = answer_generated_questions_b(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_b,\n",
    "    chunks=chunks_b,\n",
    "    client=openai_client,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "bc18c46e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Answer A (BGE + config A)</th>\n",
       "      <th>Answer B (OpenAI + config B)</th>\n",
       "      <th>Source chunk (A) preview</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What diagnostic criteria and tests are recommended for confirming asthma when spirometry is unavailable, and what steps should be taken if the diagnosis remains uncertain?</td>\n",
       "      <td>If spirometry is unavailable or delayed, it is recommended to measure peak expiratory flow (PEF) twice daily for 2 weeks. Asthma can be diagnosed if PEF variability (expressed as amplitude percentage mean) is 20% or more. \\n\\nIf asthma is not confirmed by fractional exhaled nitric oxide (FeNO), bronchodilator reversibility (BDR), or PEF variability but is still suspected on clinical grounds, one should either perform skin prick testing to house dust mite or measure total IgE level and blood eosinophil count. \\n\\n- Exclude asthma if there is no evidence of sensitization to house dust mite on skin prick testing or if the total serum IgE is not raised. \\n- Diagnose asthma if there is evidence of sensitization or a raised total IgE level, and the eosinophil count is more than 0.5 x 10^9 per liter. \\n\\nIf there is still doubt about the diagnosis, a referral to a pediatric specialist for a second opinion, including consideration of a bronchial challenge test, should be made.</td>\n",
       "      <td>If spirometry is not available or is delayed, the recommendation is to measure peak expiratory flow (PEF) twice daily for 2 weeks. Asthma can be diagnosed if PEF variability (expressed as amplitude percentage mean) is 20% or more.\\n\\nIf asthma is not confirmed by eosinophil count, F eNO, bronchodilator reversibility (BDR), or PEF variability but is still suspected on clinical grounds, a referral for consideration of a bronchial challenge test is advised. Asthma should be diagnosed if bronchial hyper-responsiveness is present.</td>\n",
       "      <td>[BTS/NICE/SIGN 202 4] \\n1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \\nDiagnose ast hma if PEF v ariability ( expressed as amplitude per centage mea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>What are the recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids and the evaluation of treatment efficacy after an initial trial period?</td>\n",
       "      <td>For managing suspected asthma in children under 5, the recommended steps regarding the use of inhaled corticosteroids (ICS) and the evaluation of treatment efficacy after an initial trial period are as follows:\\n\\n1. **Trial of ICS**: Consider an 8 to 12 week trial of twice-daily low-dose inhaled corticosteroid (ICS) as maintenance therapy, with a short-acting beta 2 agonist (SABA) for reliever therapy, if the child has symptoms indicating the need for maintenance therapy or has experienced severe acute episodes requiring hospitalization or multiple courses of oral corticosteroids.\\n\\n2. **Evaluation After Trial Period**: After the trial period, if symptoms do not resolve, take the following sequential steps:\\n   - Check inhaler technique and adherence.\\n   - Check for environmental sources of symptoms (e.g., mold, smoke, air pollution).\\n   - Review whether an alternative diagnosis is likely.\\n   - If none of these factors explain the failure to respond to treatment, refer the child to a specialist in asthma care.\\n\\n3. **Stopping Treatment**: If symptoms are resolved after the trial of ICS, consider stopping the ICS and SABA treatment after 8 to 12 weeks, and then review the symptoms after a further 3 months.\\n\\n4. **Management of Symptom Recurrence**: If symptoms resolve during the trial period but then recur by the 3-month review or if an acute episode requiring systemic corticosteroids or hospitalization occurs, restart regular ICS (starting at a low pediatric dose and titrating up to a moderate dose if needed) with SABA as needed, and consider a further trial without treatment after a subsequent review.\\n\\n5. **Further Treatment Options**: If asthma is uncontrolled on a moderate dose of ICS, consider adding a leukotriene receptor antagonist (LTRA) for a trial period of 8 to 12 weeks. If the LTRA is ineffective or not tolerated, refer the child to a specialist for further investigation and management. \\n\\nThese steps aim to carefully monitor and adjust treatment, ensuring that the child receives appropriate care based on their response to initial therapies.</td>\n",
       "      <td>The recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids (ICS) and the evaluation of treatment efficacy after an initial trial period, are as follows:\\n\\n1. **Consider an 8 to 12 week trial of twice-daily paediatric low-dose inhaled corticosteroid (ICS)** as maintenance therapy, alongside a short-acting beta 2 agonist (SABA) for reliever therapy. This is recommended for children under 5 with suspected asthma who have:\\n   - Symptoms at presentation indicating the need for maintenance therapy (e.g., interval symptoms in children with another atopic disorder).\\n   - Severe acute episodes of difficulty breathing and wheezing (e.g., requiring hospital admission or needing 2 or more courses of oral corticosteroids).\\n\\n2. **Evaluate treatment efficacy after the trial period**:\\n   - If symptoms do not resolve during this trial, sequential steps should be taken, including:\\n     - Checking inhaler technique and adherence to the treatment.\\n     - Checking for any environmental sources of the child's symptoms (e.g., mould in the home, cold housing, smokers, or indoor air pollution).\\n     - Reviewing whether an alternative diagnosis is likely.\\n   - If none of these factors explain the failure to respond to treatment, the child should be referred to a specialist in asthma care.\\n\\n3. **Consider stopping ICS and SABA treatment after 8 to 12 weeks** if symptoms are not present, as this could indicate that the ICS was beneficial and not just a result of natural improvement from a viral episode.\\n\\nOnce asthma is established with reasonable certainty, regular paediatric low-dose ICS should be restarted, and subsequent steps can be added if needed.</td>\n",
       "      <td>childr en under 5 . \\n1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \\ncorticost eroid (ICS) as maint enance t herap y (wit h a shor t-acting beta 2 agonist \\n[SABA] f ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>What are the potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients?</td>\n",
       "      <td>Implementing a risk-stratification system in primary care for improving asthma management among high-risk patients may have several implications:\\n\\n1. **Tailored Care**: It allows healthcare providers to actively identify individuals at risk of poor asthma outcomes and tailor care according to their specific needs.\\n\\n2. **Improved Identification**: By using alerts on GP computer systems, healthcare professionals can better identify patients who need interventions, such as a course of oral corticosteroids.\\n\\n3. **Reduction in Hospitalisation**: Studies show that risk stratification can lead to a reduction in emergency department attendances and hospitalisations for asthma exacerbations.\\n\\n4. **Cost-Effectiveness**: There is evidence suggesting that implementing risk stratification is likely to be cost-effective, as it can reduce the demand for emergency care and hospital admissions.\\n\\n5. **Enhanced Resource Allocation**: Primary care services can prioritize resources and focus on patients who are more likely to benefit from additional support and interventions.\\n\\nOverall, risk stratification is likely to improve asthma management and outcomes for high-risk patients while also being a more efficient use of healthcare resources.</td>\n",
       "      <td>The potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients include:\\n\\n1. **Better Identification of At-Risk Patients**: The system may help healthcare professionals identify individuals at high risk of poor asthma outcomes, allowing for more tailored care.\\n\\n2. **Reduced Hospitalisations and Emergency Visits**: Evidence from studies indicates that risk-stratified care can lead to a reduction in hospitalisations and the need for emergency department visits for asthma exacerbations.\\n\\n3. **Enhanced Management**: By actively identifying high-risk individuals, the care they receive can be adjusted according to their specific needs, possibly resulting in improved asthma control.\\n\\n4. **Cost-Effectiveness**: An associated health economic review suggests that risk stratification is likely to be cost-effective, potentially leading to savings in healthcare costs through reduced emergency care.\\n\\n5. **Changes in Practice**: For general practices that do not currently have alert systems in place, this recommendation could result in a significant change in practice, necessitating the adoption of new protocols.\\n\\n6. **Variability in Systems**: The committee noted uncertainty regarding the types of systems already in use. The implementation might lead to variation in practices across different general practices.\\n\\nOverall, the implementation of such a system is likely to improve asthma management but may also require changes in how care is currently delivered in primary care settings.</td>\n",
       "      <td>The studies f eatur ed diff ering wa ys of att empting t o impr ove ast hma car e for people \\njudged t o be at high risk of adv erse out comes. Ther efore, firm conclusions on t he overall \\nbenefit s ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>What are the different blood pressure treatment thresholds and intervention recommendations for adults under 40 and those over 80, and what factors influenced the committee's recommendations for research in these areas?</td>\n",
       "      <td>For adults under 40, the committee noted a lack of evidence to inform a specific threshold for starting treatment, indicating that this is an important area for future research. They carried forward a recommendation for research from the 2011 guideline regarding thresholds for interventions in this age group.\\n\\nFor adults over 80, the recommended threshold for starting treatment should be consistent with the target for treatment in this population, which is 150/90 mmHg or lower. The committee acknowledged additional risks associated with starting treatment in older adults, particularly those who are frail or have multiple comorbidities. They emphasized the importance of using clinical judgment in decision-making for these individuals.\\n\\nThe committee's recommendations for research in these areas were influenced by the insufficient evidence available for determining appropriate thresholds for starting treatment in both age groups, highlighting the need for more focused studies.</td>\n",
       "      <td>For adults aged under 40 with hypertension, the recommendations include considering specialist evaluation of secondary causes of hypertension and a more detailed assessment of the long-term balance of treatment benefit and risks. The specific blood pressure thresholds for starting treatment are not detailed in the provided context.\\n\\nFor people aged over 80, the recommendation is to consider antihypertensive drug treatment in addition to lifestyle advice if their clinic blood pressure is over 150/90 mmHg. The blood pressure targets for treatment are below 145/85 mmHg.\\n\\nThe committee made recommendations for research in these areas for several reasons:\\n1. For people aged over 80, there was no specific evidence, as the existing evidence was from mixed age groups and deemed too limited to support new practice recommendations.\\n2. For people with aortic aneurysm and those who have had a stroke, there was also no evidence specifically for those groups or limited evidence that did not support a new practice recommendation for stroke. \\n\\nThese factors contributed to the need for further research to clarify appropriate management in these specific populations.</td>\n",
       "      <td>see t he rationale on monit oring tr eatment and blood pr essur e tar gets for people \\nwithout car diovascular disease . \\nFull details of t he evidence and t he committ ee's discussion ar e in evidenc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>What considerations should healthcare providers keep in mind when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension, particularly regarding potassium levels and renal function?</td>\n",
       "      <td>Healthcare providers should consider the following when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension:\\n\\n1. **Potassium Levels**: \\n   - For patients starting step 4 treatment with resistant hypertension who have a blood potassium level of 4.5 mmol/l or less, further diuretic therapy with low-dose spironolactone may be considered.\\n   - If a patient has a blood potassium level of more than 4.5 mmol/l, considering an alpha-blocker or beta-blocker instead might be appropriate.\\n\\n2. **Renal Function**:\\n   - Special caution should be exercised in individuals with a reduced estimated glomerular filtration rate, as they have an increased risk of developing hyperkalaemia (elevated potassium levels).\\n\\n3. **Monitoring**: \\n   - Blood sodium and potassium levels, along with renal function, should be monitored within 1 month of starting treatment and repeated as needed thereafter.\\n\\nThese considerations are essential to minimize the risks associated with hyperkalaemia and ensure patient safety while managing resistant hypertension.</td>\n",
       "      <td>Healthcare providers should consider the following when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension:\\n\\n1. **Potassium Levels**: Providers should monitor blood potassium levels, particularly ensuring that patients starting treatment with spironolactone have a potassium level of 4.5 mmol/l or less. Caution is advised for individuals with a potassium level above this threshold.\\n\\n2. **Renal Function**: Renal function should be assessed, particularly in patients with a reduced estimated glomerular filtration rate (eGFR), as they have an increased risk of hyperkalaemia.\\n\\n3. **Monitoring**: Blood sodium, potassium levels, and renal function should be monitored within one month of starting treatment and repeated as necessary thereafter.\\n\\n4. **Combination with Other Treatments**: If blood pressure remains uncontrolled in patients already on optimal tolerated doses of four antihypertensive drugs, seeking specialist advice is recommended.\\n\\nThese considerations are crucial to manage the risks associated with diuretic therapy and to optimize treatment outcomes for patients with resistant hypertension.</td>\n",
       "      <td>clarification on br eastf eeding . \\n1.4.49 Consider fur ther diur etic t herap y wit h low-dose spir onolact one f or adult s wit h \\nresistant h yper tension star ting st ep 4 treatment who ha ve a bl...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                        Question  \\\n",
       "0                                                    What diagnostic criteria and tests are recommended for confirming asthma when spirometry is unavailable, and what steps should be taken if the diagnosis remains uncertain?   \n",
       "1            What are the recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids and the evaluation of treatment efficacy after an initial trial period?   \n",
       "2                                                                     What are the potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients?   \n",
       "3    What are the different blood pressure treatment thresholds and intervention recommendations for adults under 40 and those over 80, and what factors influenced the committee's recommendations for research in these areas?   \n",
       "4  What considerations should healthcare providers keep in mind when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension, particularly regarding potassium levels and renal function?   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Answer A (BGE + config A)  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             If spirometry is unavailable or delayed, it is recommended to measure peak expiratory flow (PEF) twice daily for 2 weeks. Asthma can be diagnosed if PEF variability (expressed as amplitude percentage mean) is 20% or more. \\n\\nIf asthma is not confirmed by fractional exhaled nitric oxide (FeNO), bronchodilator reversibility (BDR), or PEF variability but is still suspected on clinical grounds, one should either perform skin prick testing to house dust mite or measure total IgE level and blood eosinophil count. \\n\\n- Exclude asthma if there is no evidence of sensitization to house dust mite on skin prick testing or if the total serum IgE is not raised. \\n- Diagnose asthma if there is evidence of sensitization or a raised total IgE level, and the eosinophil count is more than 0.5 x 10^9 per liter. \\n\\nIf there is still doubt about the diagnosis, a referral to a pediatric specialist for a second opinion, including consideration of a bronchial challenge test, should be made.   \n",
       "1  For managing suspected asthma in children under 5, the recommended steps regarding the use of inhaled corticosteroids (ICS) and the evaluation of treatment efficacy after an initial trial period are as follows:\\n\\n1. **Trial of ICS**: Consider an 8 to 12 week trial of twice-daily low-dose inhaled corticosteroid (ICS) as maintenance therapy, with a short-acting beta 2 agonist (SABA) for reliever therapy, if the child has symptoms indicating the need for maintenance therapy or has experienced severe acute episodes requiring hospitalization or multiple courses of oral corticosteroids.\\n\\n2. **Evaluation After Trial Period**: After the trial period, if symptoms do not resolve, take the following sequential steps:\\n   - Check inhaler technique and adherence.\\n   - Check for environmental sources of symptoms (e.g., mold, smoke, air pollution).\\n   - Review whether an alternative diagnosis is likely.\\n   - If none of these factors explain the failure to respond to treatment, refer the child to a specialist in asthma care.\\n\\n3. **Stopping Treatment**: If symptoms are resolved after the trial of ICS, consider stopping the ICS and SABA treatment after 8 to 12 weeks, and then review the symptoms after a further 3 months.\\n\\n4. **Management of Symptom Recurrence**: If symptoms resolve during the trial period but then recur by the 3-month review or if an acute episode requiring systemic corticosteroids or hospitalization occurs, restart regular ICS (starting at a low pediatric dose and titrating up to a moderate dose if needed) with SABA as needed, and consider a further trial without treatment after a subsequent review.\\n\\n5. **Further Treatment Options**: If asthma is uncontrolled on a moderate dose of ICS, consider adding a leukotriene receptor antagonist (LTRA) for a trial period of 8 to 12 weeks. If the LTRA is ineffective or not tolerated, refer the child to a specialist for further investigation and management. \\n\\nThese steps aim to carefully monitor and adjust treatment, ensuring that the child receives appropriate care based on their response to initial therapies.   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Implementing a risk-stratification system in primary care for improving asthma management among high-risk patients may have several implications:\\n\\n1. **Tailored Care**: It allows healthcare providers to actively identify individuals at risk of poor asthma outcomes and tailor care according to their specific needs.\\n\\n2. **Improved Identification**: By using alerts on GP computer systems, healthcare professionals can better identify patients who need interventions, such as a course of oral corticosteroids.\\n\\n3. **Reduction in Hospitalisation**: Studies show that risk stratification can lead to a reduction in emergency department attendances and hospitalisations for asthma exacerbations.\\n\\n4. **Cost-Effectiveness**: There is evidence suggesting that implementing risk stratification is likely to be cost-effective, as it can reduce the demand for emergency care and hospital admissions.\\n\\n5. **Enhanced Resource Allocation**: Primary care services can prioritize resources and focus on patients who are more likely to benefit from additional support and interventions.\\n\\nOverall, risk stratification is likely to improve asthma management and outcomes for high-risk patients while also being a more efficient use of healthcare resources.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   For adults under 40, the committee noted a lack of evidence to inform a specific threshold for starting treatment, indicating that this is an important area for future research. They carried forward a recommendation for research from the 2011 guideline regarding thresholds for interventions in this age group.\\n\\nFor adults over 80, the recommended threshold for starting treatment should be consistent with the target for treatment in this population, which is 150/90 mmHg or lower. The committee acknowledged additional risks associated with starting treatment in older adults, particularly those who are frail or have multiple comorbidities. They emphasized the importance of using clinical judgment in decision-making for these individuals.\\n\\nThe committee's recommendations for research in these areas were influenced by the insufficient evidence available for determining appropriate thresholds for starting treatment in both age groups, highlighting the need for more focused studies.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Healthcare providers should consider the following when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension:\\n\\n1. **Potassium Levels**: \\n   - For patients starting step 4 treatment with resistant hypertension who have a blood potassium level of 4.5 mmol/l or less, further diuretic therapy with low-dose spironolactone may be considered.\\n   - If a patient has a blood potassium level of more than 4.5 mmol/l, considering an alpha-blocker or beta-blocker instead might be appropriate.\\n\\n2. **Renal Function**:\\n   - Special caution should be exercised in individuals with a reduced estimated glomerular filtration rate, as they have an increased risk of developing hyperkalaemia (elevated potassium levels).\\n\\n3. **Monitoring**: \\n   - Blood sodium and potassium levels, along with renal function, should be monitored within 1 month of starting treatment and repeated as needed thereafter.\\n\\nThese considerations are essential to minimize the risks associated with hyperkalaemia and ensure patient safety while managing resistant hypertension.   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Answer B (OpenAI + config B)  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         If spirometry is not available or is delayed, the recommendation is to measure peak expiratory flow (PEF) twice daily for 2 weeks. Asthma can be diagnosed if PEF variability (expressed as amplitude percentage mean) is 20% or more.\\n\\nIf asthma is not confirmed by eosinophil count, F eNO, bronchodilator reversibility (BDR), or PEF variability but is still suspected on clinical grounds, a referral for consideration of a bronchial challenge test is advised. Asthma should be diagnosed if bronchial hyper-responsiveness is present.   \n",
       "1  The recommended steps for managing suspected asthma in children under 5, particularly regarding the use of inhaled corticosteroids (ICS) and the evaluation of treatment efficacy after an initial trial period, are as follows:\\n\\n1. **Consider an 8 to 12 week trial of twice-daily paediatric low-dose inhaled corticosteroid (ICS)** as maintenance therapy, alongside a short-acting beta 2 agonist (SABA) for reliever therapy. This is recommended for children under 5 with suspected asthma who have:\\n   - Symptoms at presentation indicating the need for maintenance therapy (e.g., interval symptoms in children with another atopic disorder).\\n   - Severe acute episodes of difficulty breathing and wheezing (e.g., requiring hospital admission or needing 2 or more courses of oral corticosteroids).\\n\\n2. **Evaluate treatment efficacy after the trial period**:\\n   - If symptoms do not resolve during this trial, sequential steps should be taken, including:\\n     - Checking inhaler technique and adherence to the treatment.\\n     - Checking for any environmental sources of the child's symptoms (e.g., mould in the home, cold housing, smokers, or indoor air pollution).\\n     - Reviewing whether an alternative diagnosis is likely.\\n   - If none of these factors explain the failure to respond to treatment, the child should be referred to a specialist in asthma care.\\n\\n3. **Consider stopping ICS and SABA treatment after 8 to 12 weeks** if symptoms are not present, as this could indicate that the ICS was beneficial and not just a result of natural improvement from a viral episode.\\n\\nOnce asthma is established with reasonable certainty, regular paediatric low-dose ICS should be restarted, and subsequent steps can be added if needed.   \n",
       "2                                                                                                                                                        The potential implications of implementing a risk-stratification system in primary care for improving asthma management among high-risk patients include:\\n\\n1. **Better Identification of At-Risk Patients**: The system may help healthcare professionals identify individuals at high risk of poor asthma outcomes, allowing for more tailored care.\\n\\n2. **Reduced Hospitalisations and Emergency Visits**: Evidence from studies indicates that risk-stratified care can lead to a reduction in hospitalisations and the need for emergency department visits for asthma exacerbations.\\n\\n3. **Enhanced Management**: By actively identifying high-risk individuals, the care they receive can be adjusted according to their specific needs, possibly resulting in improved asthma control.\\n\\n4. **Cost-Effectiveness**: An associated health economic review suggests that risk stratification is likely to be cost-effective, potentially leading to savings in healthcare costs through reduced emergency care.\\n\\n5. **Changes in Practice**: For general practices that do not currently have alert systems in place, this recommendation could result in a significant change in practice, necessitating the adoption of new protocols.\\n\\n6. **Variability in Systems**: The committee noted uncertainty regarding the types of systems already in use. The implementation might lead to variation in practices across different general practices.\\n\\nOverall, the implementation of such a system is likely to improve asthma management but may also require changes in how care is currently delivered in primary care settings.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     For adults aged under 40 with hypertension, the recommendations include considering specialist evaluation of secondary causes of hypertension and a more detailed assessment of the long-term balance of treatment benefit and risks. The specific blood pressure thresholds for starting treatment are not detailed in the provided context.\\n\\nFor people aged over 80, the recommendation is to consider antihypertensive drug treatment in addition to lifestyle advice if their clinic blood pressure is over 150/90 mmHg. The blood pressure targets for treatment are below 145/85 mmHg.\\n\\nThe committee made recommendations for research in these areas for several reasons:\\n1. For people aged over 80, there was no specific evidence, as the existing evidence was from mixed age groups and deemed too limited to support new practice recommendations.\\n2. For people with aortic aneurysm and those who have had a stroke, there was also no evidence specifically for those groups or limited evidence that did not support a new practice recommendation for stroke. \\n\\nThese factors contributed to the need for further research to clarify appropriate management in these specific populations.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Healthcare providers should consider the following when prescribing spironolactone and other diuretic therapies for adults with resistant hypertension:\\n\\n1. **Potassium Levels**: Providers should monitor blood potassium levels, particularly ensuring that patients starting treatment with spironolactone have a potassium level of 4.5 mmol/l or less. Caution is advised for individuals with a potassium level above this threshold.\\n\\n2. **Renal Function**: Renal function should be assessed, particularly in patients with a reduced estimated glomerular filtration rate (eGFR), as they have an increased risk of hyperkalaemia.\\n\\n3. **Monitoring**: Blood sodium, potassium levels, and renal function should be monitored within one month of starting treatment and repeated as necessary thereafter.\\n\\n4. **Combination with Other Treatments**: If blood pressure remains uncontrolled in patients already on optimal tolerated doses of four antihypertensive drugs, seeking specialist advice is recommended.\\n\\nThese considerations are crucial to manage the risks associated with diuretic therapy and to optimize treatment outcomes for patients with resistant hypertension.   \n",
       "\n",
       "                                                                                                                                                                                         Source chunk (A) preview  \n",
       "0   [BTS/NICE/SIGN 202 4] \\n1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \\nDiagnose ast hma if PEF v ariability ( expressed as amplitude per centage mea...  \n",
       "1  childr en under 5 . \\n1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \\ncorticost eroid (ICS) as maint enance t herap y (wit h a shor t-acting beta 2 agonist \\n[SABA] f ...  \n",
       "2   The studies f eatur ed diff ering wa ys of att empting t o impr ove ast hma car e for people \\njudged t o be at high risk of adv erse out comes. Ther efore, firm conclusions on t he overall \\nbenefit s ...  \n",
       "3   see t he rationale on monit oring tr eatment and blood pr essur e tar gets for people \\nwithout car diovascular disease . \\nFull details of t he evidence and t he committ ee's discussion ar e in evidenc...  \n",
       "4   clarification on br eastf eeding . \\n1.4.49 Consider fur ther diur etic t herap y wit h low-dose spir onolact one f or adult s wit h \\nresistant h yper tension star ting st ep 4 treatment who ha ve a bl...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "rows = []\n",
    "\n",
    "for qa_a, qa_b in zip(results_a, results_b):\n",
    "    rows.append({\n",
    "        \"Question\": qa_a[\"question\"],\n",
    "        \"Answer A (BGE + config A)\": qa_a[\"answer\"],\n",
    "        \"Answer B (OpenAI + config B)\": qa_b[\"answer\"],\n",
    "        \"Source chunk (A) preview\": qa_a[\"chunk\"][:200] + \"...\"\n",
    "    })\n",
    "\n",
    "df_comparison = pd.DataFrame(rows)\n",
    "display(df_comparison)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d06db215",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
